Research Analysts Set Expectations for MLYS FY2029 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Analysts at HC Wainwright upped their FY2029 earnings per share estimates for Mineralys Therapeutics in a note issued to investors on Monday, March 16th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of $1.56 for the year, up from their previous forecast of $1.54. HC Wainwright currently has a “Buy” rating and a $56.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ FY2030 earnings at $4.55 EPS.

MLYS has been the subject of several other reports. Wall Street Zen raised shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Jefferies Financial Group reaffirmed a “hold” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a report on Friday, March 13th. Bank of America boosted their target price on Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Stifel Nicolaus increased their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.14.

Mineralys Therapeutics Stock Performance

MLYS stock opened at $23.90 on Tuesday. The stock has a market capitalization of $1.97 billion, a PE ratio of -10.08 and a beta of 0.57. The company has a fifty day moving average of $29.81 and a 200-day moving average of $35.71. Mineralys Therapeutics has a one year low of $10.44 and a one year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17.

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds have recently bought and sold shares of the company. Navalign LLC acquired a new position in Mineralys Therapeutics during the fourth quarter worth $33,000. Smartleaf Asset Management LLC grew its holdings in Mineralys Therapeutics by 198.2% in the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Mineralys Therapeutics by 42.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after buying an additional 1,197 shares in the last quarter. Royal Bank of Canada increased its position in shares of Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after buying an additional 1,107 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Mineralys Therapeutics by 1,845.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after buying an additional 1,993 shares during the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 10,758 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.14, for a total transaction of $345,762.12. Following the sale, the chief financial officer owned 8,638 shares of the company’s stock, valued at approximately $277,625.32. The trade was a 55.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David Malcom Rodman sold 14,058 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.26, for a total transaction of $369,163.08. Following the transaction, the insider owned 76,140 shares in the company, valued at $1,999,436.40. The trade was a 15.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 363,325 shares of company stock worth $12,298,347 over the last 90 days. Company insiders own 25.56% of the company’s stock.

Key Headlines Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS for Q1–Q3 2026 and bumped its FY2026 estimate (now ($2.14)), while maintaining a “Buy” rating and $56 target — a vote of confidence that can support the stock. HC Wainwright note on MLYS
• Positive Sentiment: Company update: Mineralys reported 2025 results and said it advanced the regulatory review for its hypertension candidate (lorundrostat) — regulatory progress and clinical milestones are key upside catalysts for a clinical‑stage biotech. Mineralys reports 2025 results (MSN)
• Positive Sentiment: Institutional demand: recent 1Q filings show new/expanded positions from AQR, Goldman Sachs, Woodline and others — heavy institutional ownership (≈84%) can amplify moves and indicates investor interest. MLYS institutional holdings
• Neutral Sentiment: Analyst mix and consensus: despite several Buy ratings (6 Buys, 1 Hold, 1 Sell) the street still expects sizeable negative EPS this year (consensus ≈ -4.23), and the consensus target (~$49) remains well above the current price — signals both long‑term upside expectations and near‑term valuation risk. MarketBeat analyst summary
• Negative Sentiment: Insider selling: Director/insider David Malcom Rodman has sold multiple sizable blocks recently (including 6,348 shares on Mar 12), which can be read as near‑term selling pressure or profit‑taking. Insider trades alert
• Negative Sentiment: Offsetting estimate cuts: HC Wainwright trimmed FY2027 and FY2028 EPS forecasts slightly (and nudged Q4 2026 a touch weaker), showing some longer‑horizon uncertainty despite near‑term upgrades — these downgrades add caution for longer‑dated expectations. HC Wainwright detail

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.